Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001897612-25-000555
Filing Date
2025-11-14
Accepted
2025-11-14 12:18:25
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 5673
  Complete submission text file 0001897612-25-000555.txt   7308
Mailing Address 60 FIRST ST. CAMBRIDGE MA 02141
Business Address 60 FIRST ST. CAMBRIDGE MA 02141 617-465-0013
Prime Medicine, Inc. (Subject) CIK: 0001894562 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-93800 | Film No.: 251483388
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 1307 POINT STREET BALTIMORE MD 21231
Business Address 1307 POINT STREET BALTIMORE MD 21231 000-000-0000
T. Rowe Price Investment Management, Inc. (Filed by) CIK: 0001897612 (see all company filings)

EIN.: 854328500 | State of Incorp.: MD | Fiscal Year End: 1231
Type: SCHEDULE 13G